You're getting 1/3 or shares free as an options, as soon as CR saga settles the SP appreciation will start as institutional entitlement is non-renounceable offer so they are not selling. The price target is $6.50 if successful after Phase 3 readouts for COAST (Combination OPT-302 with Aflibercept Study), and ShORe (Study of OPT-302 in combination with Ranibizumab),
The safety and superior efficacy of Sozinibercept is proven, than Sky is the limit after next readout
Ann: Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens, page-5
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
0.005(1.45%) |
Mkt cap ! $376.5M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 34.0¢ | $119.8K | 347.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 84756 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 1377477 | 12 |
View Market Depth
| Last trade - 11.15am 25/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |